Pharvaris (NASDAQ:PHVS – Get an assessment) had its target price reduced by SVB Leerink from $45.00 to $25.00 in a report on Tuesday, reports The Fly. SVB Leerink’s target price indicates an upside potential of 105.85% from the current share price.
Several other research companies have also recently published reports on PHVS. Bank of America downgraded Pharvaris from a “neutral” rating to an “underperforming” rating in a research report on Monday. Oppenheimer reduced his target price on Pharvaris from $48.00 to $22.00 in a research note on Tuesday. Morgan Stanley downgraded Pharvaris from an “overweight” rating to an “equally weighted” rating and lowered its price target for the company from $40.00 to $10.00 in a research note on Tuesday. Finally, JMP Securities began covering Pharvaris shares in a report on Wednesday, May 25. They set an “outperform” rating and a target price of $34.00 for the company.
Phavaris Price Performance
Shares of Pharvaris opened at $12.15 on Tuesday. The company has a 50-day simple moving average of $21.30 and a 200-day simple moving average of $19.00. The company has a market capitalization of $386.70 million, a price-earnings ratio of -4.67 and a beta of -0.79. Pharvaris has a 1-year low of $11.06 and a 1-year high of $27.50.
Institutional investors weigh in on Pharvaris
Hedge funds have recently changed their stakes in the company. Viking Global Investors LP increased its stake in Pharvaris shares by 1.0% during the 1st quarter. Viking Global Investors LP now owns 2,480,319 shares of the company valued at $46,382,000 after purchasing an additional 24,783 shares last quarter. Suvretta Capital Management LLC purchased a new stake in shares of Pharvaris in Q4 for a value of approximately $11,908,000. Novo Holdings AS increased its equity stake in Pharvaris by 23.2% in the 4th quarter. Novo Holdings AS now owns 516,321 shares of the company worth $7,430,000 after purchasing an additional 97,378 shares in the last quarter. Eventide Asset Management LLC increased its stake in Pharvaris shares by 23.6% in the 1st quarter. Eventide Asset Management LLC now owns 302,619 shares of the company worth $5,659,000 after purchasing an additional 57,694 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Pharvaris shares by 2.0% in the 2nd quarter. Goldman Sachs Group Inc. now owns 56,951 shares of the company worth $1,259,000 after buying 1,115 additional shares in the last quarter. Institutional investors hold 79.32% of the company’s shares.
(Get a rating)
Pharvaris NV, a clinical-stage biopharmaceutical company, is focused on developing and commercializing therapies for rare diseases. The company is developing PHA121, a small molecule bradykinin B2 receptor antagonist that is in a phase II clinical trial for the treatment of hereditary angioedema (HAE).
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to email@example.com.
Before you consider Pharvaris, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Pharvaris didn’t make the list.
Although Pharvaris currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the five actions here